FTC approves Actavis/Warner Chilcott with drug rights divestments

30 September 2013

FTC approves Actavis/Warner Chilcott with drug rights divestments Actavis must divest the rights to oral contraceptive Loestrin

The US Federal Trade Commission has approved Actavis’s US$8.5 billion acquisition of Irish rival Warner Chilcott on condition it sells the rights to four generic drugs.